The new treatments Gilhooley referred to are calcitonin gene-related peptide (CGRP) inhibitors, a class that includes ...

Pain from around or behind the eyes is a feature of many headaches. But that doesn't mean that there aren't painful eye ...

Gilhooley noted that the large trigeminal nerve that innervates the face and the scalp also branches out to the eye. Ophthalmologists can play a role in ferreting out the cause of a headache because a ...

That is the number for the Current Procedural Terminology (CPT) code for using autonomous AI to diagnose diabetic retinopathy, a widespread application of AI in ophthalmology and one of the most ...

Here’s what you missed this week on Managed Healthcare Executive. Each Sunday we feature a highlight reel of various articles ...

Alfredo A. Sadun, M.D., Ph.D., discusses two applications of AI in ophthalmology where AI far exceeds what a human ophthalmologist can do. Many people worry about artificial intelligence (AI) ...

At the American Academy of Ophthalmology meeting, Andrew G. Lee, M.D., explained that El Niño and La Niña weather patterns—worsened by climate change—can worsen eye conditions such as dry eye, ...

A study using AAO's IRIS Registry demonstrates Eylea HD 8 mg improves vision in treatment-naive patients with wet age-related macular degeneration or diabetic macular edema with previously treated ...

Positive results for Hernexeos (zongertinib) as a first-line treatment for non-small cell lung cancer (NSCLC) with HER2 mutations were reported yesterday at the European Society for Medical Oncology ...

They say that a picture is worth a thousand words. But images are also dense with data and that is why ophthalmology is the vanguard of specialties using artificial intelligence (AI), explains Alfredo ...

Overall, the median duration of b/tsDMARD use was 4.3 years, longer in RA (6.3 years) than axSpA (3 years). TNF inhibitors were the most commonly used treatment (80.7%), with axSpA patients more often ...

Neil Bressler, M.D., a professor of ophthalmology at Johns Hopkins and editor-in-chief of JAMA Ophthalmology, argued that complement inhibition for geographic atrophy is a game changer. His debating ...